Evidence map›Paper›PMID 16200408›Full record

ArticlePlanta2006

Expression of the ubiquitin variant ubR48 decreases proteolytic activity in Arabidopsis and induces cell death.

Peter Schlögelhofer, Marcus Garzón, Claudia Kerzendorfer, Viktoria Nizhynska, Andreas Bachmair

Abstract read
PubMed Publisher
In one paragraph

Article in Planta, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Peter SchlögelhoferInstitute of Botany, University of Vienna, Austria.
Marcus Garzón
Claudia Kerzendorfer
Viktoria Nizhynska
Andreas Bachmair
University of Vienna · ATMax Planck Institute for Plant Breeding Research · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The ubiquitin-proteasome pathway is the major route for protein degradation in eukaryotes. We show here that this pathway can be inhibited in Arabidopsis thaliana by expression of a ubiquitin variant that contains Arg instead of Lys at position 48 (ubR48). A major consequence of ubR48 expression is the induction of cell death. Cell death induction coincides with the appearance of reactive oxygen intermediates, but is independent of salicylic acid. We found changes in expression of some defense-related genes, but these changes are apparently insufficient to cause alterations in the response to a bacterial pathogen. Expression of ubR48 from an inducible gene allowed investigation of kinetic parameters of cell death induction. In the absence of additional stress factors, slow death processes dominate if the transgene is induced in seedlings older than 2 weeks. The inducible gene also allowed isolation of suppressor mutants. Expression of ubR48 may cause changes similar to inhibition of the proteasome, which also induces various forms of cell death. Thus, ubR48 is a tool to manipulate protein turnover and to probe cell death programs in plants.

Indexed as

ApoptosisArabidopsisArabidopsis ProteinsCyclopentanesDexamethasoneGene Expression Regulation, PlantGenes, PlantLeupeptinsMutationOxylipinsPhenotypePlant Growth RegulatorsPlant LeavesPlants, Genetically ModifiedProteasome Endopeptidase ComplexSalicylic AcidArabidopsis Proteinsbenzyloxycarbonylleucyl-leucyl-leucine aldehydeCyclopentanesDexamethasonejasmonic acidLeupeptinsOxylipinsPlant Growth RegulatorsPR-1 protein, ArabidopsisProteasome Endopeptidase ComplexSalicylic AcidUbiquitin

Identifiers

PMID16200408
OpenAlexW2047794714

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.